PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Pregabalin - Pain (Neuropathic)

PAD Profile : Pregabalin - Pain (Neuropathic)

Keywords :
diabetic neuropathy, postherpetic neuralgia, PHN, neuropathic pain
Brand Names Include :
Lyrica

Traffic Light Status

Status 1 of 3.

Status :
Green (see narrative)
Important
Formulations :
  • Capsules
Important Information :
Gabapentin is preferred due to lower potential for misuse. Pregabalin capsules more cost effective than tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
SA
Comments :
No comments returned.
Documents :

Status 2 of 3.

Status :
Green (see narrative)
Formulations :
  • Oral solution
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
Non Formulary
Formulations :
  • Modified release tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :

Pregabalin modified release tablets have not yet been assessed for formulary status and are not currently on the APC work-plan.

They have not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Prescribers are reminded to undertake a proportionate risk benefit assessment prior to prescribing Pregabalin or Gabapentin for patients with a known or suspected propensity to misuse. See Advice for Prescribers document below

Associated BNF Codes

04. Central Nervous System
04.07.03. Neuropathic pain
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More